User login
Key clinical point: Low serum levels of vitamin D are inversely associated with clinical and disease activity in patients with multiple sclerosis (MS).
Major finding: Patients with serum 25(OH)D levels ≥30 ng/mL group had lower median T2-weighted lesion counts than those with <30 ng/mL (P = .03; adjusted for age, sex, 25(OH)D levels, and disease duration, P less than .001). Expanded disability status scale (EDSS) score had an inverse association with serum 25(OH)D levels after adjusting for age, sex, and disease duration (adjusted P less than .001).
Study details: The study analyzed baseline serum vitamin D levels of patients recruited in the randomized Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS) study.
Disclosures: The study was funded by the German Research Organization grants awarded to FP and JD, the Einstein Foundation Berlin, and a limited research grant from Bayer Leverkusen, Germany. Priscilla Bäcker-Koduah, Judith Bellmann-Strobl, Jens Wuerfel, Jan Dörr, Alexander Ulrich Brandt, Friedemann Paul, Klaus-Dieter Wernecke reported ties with one or more pharmaceutical companies. Michael Scheel reported no conflicts of interest.
Citation: Bäcker-Koduah P et al. Front Neurol. 2020 Feb 25. doi: 10.3389/fneur.2020.00129.
Key clinical point: Low serum levels of vitamin D are inversely associated with clinical and disease activity in patients with multiple sclerosis (MS).
Major finding: Patients with serum 25(OH)D levels ≥30 ng/mL group had lower median T2-weighted lesion counts than those with <30 ng/mL (P = .03; adjusted for age, sex, 25(OH)D levels, and disease duration, P less than .001). Expanded disability status scale (EDSS) score had an inverse association with serum 25(OH)D levels after adjusting for age, sex, and disease duration (adjusted P less than .001).
Study details: The study analyzed baseline serum vitamin D levels of patients recruited in the randomized Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS) study.
Disclosures: The study was funded by the German Research Organization grants awarded to FP and JD, the Einstein Foundation Berlin, and a limited research grant from Bayer Leverkusen, Germany. Priscilla Bäcker-Koduah, Judith Bellmann-Strobl, Jens Wuerfel, Jan Dörr, Alexander Ulrich Brandt, Friedemann Paul, Klaus-Dieter Wernecke reported ties with one or more pharmaceutical companies. Michael Scheel reported no conflicts of interest.
Citation: Bäcker-Koduah P et al. Front Neurol. 2020 Feb 25. doi: 10.3389/fneur.2020.00129.
Key clinical point: Low serum levels of vitamin D are inversely associated with clinical and disease activity in patients with multiple sclerosis (MS).
Major finding: Patients with serum 25(OH)D levels ≥30 ng/mL group had lower median T2-weighted lesion counts than those with <30 ng/mL (P = .03; adjusted for age, sex, 25(OH)D levels, and disease duration, P less than .001). Expanded disability status scale (EDSS) score had an inverse association with serum 25(OH)D levels after adjusting for age, sex, and disease duration (adjusted P less than .001).
Study details: The study analyzed baseline serum vitamin D levels of patients recruited in the randomized Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS) study.
Disclosures: The study was funded by the German Research Organization grants awarded to FP and JD, the Einstein Foundation Berlin, and a limited research grant from Bayer Leverkusen, Germany. Priscilla Bäcker-Koduah, Judith Bellmann-Strobl, Jens Wuerfel, Jan Dörr, Alexander Ulrich Brandt, Friedemann Paul, Klaus-Dieter Wernecke reported ties with one or more pharmaceutical companies. Michael Scheel reported no conflicts of interest.
Citation: Bäcker-Koduah P et al. Front Neurol. 2020 Feb 25. doi: 10.3389/fneur.2020.00129.